Wave Life Sciences Ltd.
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans
Summary
Wave Life Sciences Ltd. announced positive proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD), demonstrating the first-ever clinical demonstration of RNA editing in humans. A single subcutaneous dose of WVE-006 resulted in mean plasma total AAT levels of ~11 micromolar, with mean wild-type M-AAT representing more than 60% of total AAT. Wave expects to share multidose data from the trial in 2025.
Get alerts for WVE
Be first to know when Wave Life Sciences Ltd. files with the SEC.
Filing Categories
Exhibits (1)
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd. is a biotechnology company engaged in the research and development of stereopure nucleic acid therapies. The primary focus of Wave Life Sciences is to leverage its unique platform to design and optimize therapies that modulate RNA to address genetic diseases. This involves developing treatments with high specificity and efficacy, potentially offering advantages over traditional nucleic acid therapies. The company targets a range of serious diseases, including those related to the central nervous system, with its innovative therapies. Wave Life Sciences plays a significant role in the biopharmaceutical industry by expanding the potential of gene medicine. Its work has implications for sectors such as healthcare and pharmaceuticals, especially in developing new treatment modalities for unmet medical needs. The company's research and development efforts are geared towards delivering transformational outcomes for patients, positioning it as a pioneer in the evolving field of genetic medicine. Wave Life Sciences Ltd. claims a critical space within the market for its advancements in precision medicine and continues to collaborate with various stakeholders to push the boundaries of therapeutic development.
Official SEC Documents